- Participants who have had chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to study day 1 (6 weeks for nitrosoureas or mitomycin C) or who has not recovered (i.e., < grade 1 or at baseline) from adverse events due to previously administered agents. Note: subjects with < grade 2 peripheral neuropathy are an exception to this criterion and may qualify for the study.